Amorphous Pharmaceuticals, Cannabinoids and Related API’s

Professor Yarger has an active research group in amorphous pharmaceuticals and the physical chemistry of active pharmaceutical ingredients (API’s).  There has been a recent national interest in cannabinoids and API’s related to the hemp (cannabis) plant.  Below is some general ‘News’ in this area.

We need to get out several papers on our Cannabinoid NMR, ASDs and related research!! This was a nice figure I recently saw that is being published soon.


Good Blog Post on NMR of CBD/THC.

Netzsch Webinar – Thermal Analysis – Pharmaceuticals, July 23, 2020 | 11 am (CEST)

Bruker NMR Webinar – Prof. Eric Munson – July 28th 2020

Characterizing Pharmaceutical Formulations Using Solid-State NMR Spectroscopy

Overview

Advanced analytical techniques can provide unique insight into the composition and properties of pharmaceutical formulations. In particular, both structural and mobility information can be obtained about the formulations, but the challenge is to relate that information to functional properties such as physical and chemical stability, dissolution rate, and processing parameters. Solid-state NMR spectroscopy is a powerful technique to study polymorphism, form changes upon processing, the presence of small amounts of amorphous drug in crystalline solids (for chemical/physical stability), and small amounts of crystalline drug in amorphous solid dispersions (for physical stability). Solid-state NMR relaxation times have been used to measure particle size, crystal defects, and chemical impurities in crystalline materials. In addition, relaxation times have been used to determine the phase separation of amorphous formulations. Finally, mobility, phase separation, and microenvironment acidity has been studied to predict stability in large-molecule formulations.

Fully automated chemistry and biochemistry labs…. Its not just the future, its happening TODAY!! “A mobile robotic chemist” Nature volume 583, pages237–241(2020). The robot operated autonomously over eight days, performing 688 experiments within a ten-variable experimental space, driven by a batched Bayesian search algorithm

Cannabis/Hemp Web-Site and Recent Articles:

May 2020 | Argonne National Labs – APS

Laboratory powder diffraction is a proven and trusted technique for pharma R&D, but synchrotron powder diffraction pushes beyond the capabilities of conventional instrumentation. SPS-XRPD-3 will highlight the most exciting recent developments and opportunities in pharmaceutical R&D made possible by synchrotron XRPD. The meeting offers the chance to engage an active network of synchrotron, academic and industrial pharmaceutical scientists, promote awareness of this technique and lower the barriers to access synchrotron XRPD and total scattering techniques.

Feb 2020 | Chemical and Engineering News

Dec. 2019 – Feb. 2020 | ASU, Vext and BioSciTech

NIH: Notice of Special Interest: Exploring the Mechanisms Underlying Analgesic Properties of Minor Cannabinoids and Terpenes

Notice Number: NOT-AT-20-002

Key Dates
Release Date: December 13, 2019
First Available Due Date: February 05, 2020
Expiration Date: January 08, 2022

Issued by
National Center for Complementary and Integrative Health (NCCIH)

Purpose

Through this Notice of Special Interest (NOSI), the National Center for Complementary and Integrative Health (NCCIH) announces its interest in supporting research grant applications to study minor cannabinoids and terpenes in the cannabis plant as it relates to pain and/or nociception. Minor cannabinoids are defined as any and all cannabinoids from the cannabis plant other than ?9-tetrahydrocannabinol (?9-THC). Cannabinoids and terpenes of particular interest include the following: Cannabidiol (CBD), Cannabigerol (CBG), Cannabinol (CBN), Cannabichromene (CBC), Myrcene, ß-caryophyllene, Limonene, a-terpineol, Linalool, a-phellandrene, a-pinene, ß-pinene, ?-terpinene, and a -humulene. Through this NOSI, NCCIH intends to support highly innovative basic and/or mechanistic studies in appropriate model organisms and/or human subjects aiming to investigate the input of minor cannabinoids and terpenes on mechanisms underlying analgesia or pain relief.

The mechanisms and processes underlying potential contribution of minor cannabinoids and terpenes to pain relief and functional restoration may be very broad encompassing different pain conditions. This NOSI encourages interdisciplinary collaborations among experts from multiple fields, such as pharmacologists, chemists, physicists, physiologists, neuroscientists, psychologists, endocrinologists, immunologists, geneticists, behavioral scientists, clinicians, or others in relevant areas of inquiry.

Tuesday, Dec 17, 2019 | ASU

LongASU

Dec 6, 2019 | USA

https://rouda.house.gov/media/press-releases/congressman-rouda-and-senator-schatz-lead-bipartisan-letter-ag-barr-improving

DOJCannabisLetter2019

FINAL Letter to DOJ re. cannabis research and hemp, 12-6-2019

Wednesday, Dec 4, 2019 | ASU

Screen Shot 2019-11-19 at 9.06.15 PM

Discovery Series flier_Paul Hergenrother_Final

Friday, Nov. 22, 2019 | General News

More Act Passed.

Friday,  Nov. 8, 2019 | ASU

Screen Shot 2019-11-19 at 9.11.00 PM

November 2019 | AZ Cannabis

AZ_Map_Medical_Cannabis.jpg

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close